Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

被引:4
|
作者
Savvidou, A. [1 ,2 ]
Jennions, E. [1 ,2 ]
Wikstrom, S. [3 ,4 ]
Olsson-Engman, M. [5 ]
Sofou, K. [1 ,2 ]
Darin, N. [1 ,2 ]
机构
[1] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Pediat, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Cty Council Varmland, Ctr Clin Res & Educ, Varmland, Sweden
[4] Orebro Univ, Sch Med Sci, Orebro, Sweden
[5] Blekinge Hosp, Pediat Clin, Karlskrona, Sweden
关键词
Juvenile neuronal ceroid lipofuscinosis; CLN3; Neuroleptic malignant syndrome; Serotonin syndrome; Rhabdomyolysis; Neuroleptic malignant; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;
D O I
10.1016/j.ejpn.2022.06.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
CLN3 disease (MIM# 204200), the most prevalent of the neuronal ceroid lipofuscinoses (NCL), is an autosomal recessive disorder with juvenile onset characterized by blindness, epilepsy, dementia, psychiatric manifestations, and motor deterioration. Problems related to behavior, emotions and thought are among the main features. Antidepressant and antipsychotic drugs have been employed with variable results. Neuroleptic malignant syndrome (NMS) has previously been described in two patients with NCL, one with CLN3 disease and one with adult onset NCL of unclear genetic origin. Our aims were to describe the occurrence of drug-induced hyperthermia in pediatric patients with CLN3 disease from West and South Sweden and to delineate the range of associated clinical features. Our study identified four patients presenting with seven episodes of severe drug-induced hyperthermia and either NMS-like or Serotonin syndrome (SS)-like features. Possibly provoking drugs were risperidone, clozapine, olanzapine, haloperidol, quetiapine, and sertraline. The course was atypical, frequently prolonged, associated with rhabdomyolysis and status dystonicus, and resulted in the death of three of the patients. Our study points to a vulnerability to drug-induced hyperthermia in patients with CLN3 disease which we believe could be underreported. Interestingly the proposed pathophysiological mechanisms behind NMS and SS on one hand and CLN3 on the other hand seem to converge in a common mechanism involving dysregulation of the sympathetic nervous system.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
  • [31] DRUG-INDUCED RHABDOMYOLYSIS MECHANISMS AND MANAGEMENT
    PRENDERGAST, BD
    GEORGE, CF
    POSTGRADUATE MEDICAL JOURNAL, 1993, 69 (811) : 333 - 336
  • [32] Methods for quantitative gait analysis in CLN3 disease
    Zimmerman, Grace
    Vierhile, Amy
    Adams, Heather
    Mink, Jonathan
    Augustine, Erika
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S166 - S166
  • [33] IDENTIFICATION OF POTENTIAL BIOMARKERS AND MODIFIERS OF CLN3 DISEASE
    Lebrun, A. H.
    Moll-Kosrawi, P.
    Storch, S.
    Pohl, S.
    Kilian, D.
    Streichert, T.
    Mole, S. E.
    Ullrich, K.
    Kohlschutter, A.
    Braulke, T.
    Schulz, A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S140 - S140
  • [34] Exogenous Flupirtine as Potential Treatment for CLN3 Disease
    Maalouf, Katia
    Makoukji, Joelle
    Saab, Sara
    Makhoul, Nadine J.
    Carmona, Angelica V.
    Kinarivala, Nihar
    Ghanem, Noel
    Trippier, Paul C.
    Boustany, Rose-Mary
    CELLS, 2020, 9 (08) : 1 - 18
  • [35] Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease)
    Wager, Kim
    Zdebik, Anselm A.
    Fu, Sonia
    Cooper, Jonathan D.
    Harvey, Robert J.
    Russell, Claire
    PLOS ONE, 2016, 11 (06):
  • [36] A proposed staging system for CLN3 disease (juvenile Batten disease)
    Mink, Jonathan W.
    Williams, Justin D.
    Augustine, Erika F.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S96 - S96
  • [37] The CLN3 Disease Staging System (CLN3SS): A tool for stratification based on disease severity
    Masten, Margaux C.
    Williams, Justin D.
    Augustine, Erika F.
    Vermilion, Jennifer
    Adams, Heather R.
    Vierhile, Amy
    Thatcher, Alyssa
    Marshall, Frederick J.
    Mink, Jonathan W.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S106 - S106
  • [38] Developing A Staging System for Juvenile Batten Disease (CLN3 Disease)
    Williams, J.
    Augustine, E.
    Mink, J.
    ANNALS OF NEUROLOGY, 2017, 82 : S307 - S307
  • [39] The natural history of juvenile Batten disease (JNCL; CLN3 disease)
    Mink, Jonathan
    Augustine, Erika F.
    Marshall, Frederick J.
    Adams, Heather R.
    Kwon, Jennifer M.
    Vierhile, Amy
    de Blieck, Elisabeth A.
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S66 - S66
  • [40] Immunochemical localization of the Batten disease (CLN3) protein in retina
    Katz, ML
    Gao, CL
    Prabhakaram, M
    Shibuya, H
    Liu, PC
    Johnson, GS
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (11) : 2375 - 2386